日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Loss of miR-29a/b1 cluster reprograms the tumor microenvironment and contributes to immunosuppression in lung cancer

miR-29a/b1簇的缺失会重编程肿瘤微环境,并导致肺癌的免疫抑制。

Horvat, Natalie K; Saint-Cloud, Myritney; Bint Abdullah Muslim, Raihaanah; Tian, Yanhua; Rodriguez, B Leticia; Hall, Margaret A; Labani-Motlagh, Alireza; Diao, Lixia; Wang, Jing; Lesinski, Gregory B; Moffitt, Richard A; Gibbons, Don L; Konen, Jessica M

Bacteriophage therapy for the treatment of Mycobacterium tuberculosis infections in humanized mice

噬菌体疗法用于治疗人源化小鼠的结核分枝杆菌感染

Yang, Fan; Labani-Motlagh, Alireza; Bohorquez, Jose Alejandro; Moreira, Josimar Dornelas; Ansari, Danish; Patel, Sahil; Spagnolo, Fabrizio; Florence, Jon; Vankayalapati, Abhinav; Sakai, Tsuyoshi; Sato, Osamu; Ikebe, Mitsuo; Vankayalapati, Ramakrishna; Dennehy, John J; Samten, Buka; Yi, Guohua

Development of a human glioblastoma model using humanized DRAG mice for immunotherapy

使用人源化 DRAG 小鼠开发人类胶质母细胞瘤模型用于免疫治疗

Rashmi Srivastava, Alireza Labani-Motlagh, Apeng Chen, Jose Alejandro Bohorquez, Bin Qin, Meghana Dodda, Fan Yang, Danish Ansari, Sahil Patel, Honglong Ji, Scott Trasti, Yapeng Chao, Yash Patel, Han Zou, Baoli Hu, Guohua Yi

The role of NK and NKT cells in the pathogenesis and improvement of multiple sclerosis following disease-modifying therapies

NK细胞和NKT细胞在多发性硬化症的发病机制和疾病修饰疗法后的改善中的作用

Ahmadi, Alireza; Fallah Vastani, Zahra; Abounoori, Mahdi; Azizi, Mahdieh; Labani-Motlagh, Alireza; Mami, Sajad; Mami, Sanaz

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy

利用溶瘤病毒基因疗法同时靶向 CD40/4-1BB 来增强淋巴瘤中的 CAR T 细胞反应

Jessica Wenthe ,Sedigheh Naseri ,Alireza Labani-Motlagh ,Gunilla Enblad ,Kristina I Wikström ,Emma Eriksson ,Angelica Loskog # ,Tanja Lövgren #

Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes

肿瘤来源的外泌体可能支持携带免疫刺激基因的局部溶瘤病毒治疗后的全身免疫

Alireza Labani-Motlagh, Sedigheh Naseri, Jessica Wenthe, Emma Eriksson, Angelica Loskog

91 Efficacy of Venom Immunotherapy Given Every 3 or 4 Months. A Direct Prospective Comparison With the Conventional Regimen

91. 每3或4个月进行一次毒液免疫疗法的疗效。与传统疗法的直接前瞻性比较

Srivastava, Rashmi; Labani-Motlagh, Alireza; Chen, Apeng; Yang, Fan; Ansari, Danish; Patel, Sahil; Ji, Honglong; Trasti, Scott; Dodda, Meghana; Patel, Yash; Zou, Han; Hu, Baoli; Yi, Guohua; Simioni, Livio; Vianello, Alberto; Bonadonna, Patrizia; Marcer, Guido; Severino, Maurizio; Pagani, Mauro; Morlin, Luca; Crivellaro, Mariangiola; Passalacqua, Giovanni